Drugs / AVB-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05538624 | Dec 2022 → Apr 2024 | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | Avenge Bio, Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05538624 ↗ |
| Modality | Cell therapy | “AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2).” NCT05538624 ↗ |